


In the Claims


Please cancel Claim 5 without prejudice or disclaimer of any of the subject matter contained herein.

Please amend the claims as follows:

1. (Amended) A compound represented by structure I



wherein R is



where

R^a and R^{a'} are independently hydrogen or methyl, or either R^a or R^{a'} is alkyl amino, taken together with R^b or R^{b'} forms a six-membered cycloalkyl ring, a six-membered aromatic ring or a double bond, or taken together with R^c forms a six-membered aromatic ring;

R^b and R^{b'} are independently hydrogen, halogen, or methyl, or either R^b or R^{b'} is amino, alkylamino, α -acetoacetate, methoxy, or hydroxy provided that R^{b'} is not

hydroxy when R^a, R^b, R^d, R^e are hydrogen, R^c is hydrogen and R^f is n-hexyl, n-octyl or n-decyl, or R^a, R^b, R^d, R^e are hydrogen, R^c is hydroxy and R^f is n-octyl, n-nonyl, or n-decyl;


R^c is hydrogen, hydroxy, C₁-C₄ alkoxy, hydroxalkoxy, or taken together with R^e forms a 6-membered aromatic ring or C₅-C₆ cycloalkyl ring;

R^d is hydrogen;

R^e is hydrogen, or taken together with R^f is a six-membered aromatic ring, C₅-C₁₄ alkoxy substituted six-membered aromatic ring, or C₅-C₁₄ alkyl substituted six-membered aromatic ring, and

R^f is C₈-C₁₈ alkyl, C₅-C₁₁ alkoxy, or biphenyl; or

R is




where

R^g is hydrogen, or C₁-C₁₃ alkyl, and

R^h is C₁-C₁₅ alkyl, C₄-C₁₅ alkoxy, (C₁-C₁₀ alkyl)phenyl, -(CH₂)_n-aryl, or -(CH₂)_n-(C₅-C₆ cycloalkyl), where n = 1-2; or

R is




where

Rⁱ is a hydrogen, halogen, or C₅-C₈ alkoxy, and

m is 1, 2 or 3;


R is



where

R^j is C₅-C₁₄ alkoxy or C₅-C₁₄ alkyl, and p = 0, 1 or 2;

R is



where

R^k is C₅-C₁₄ alkoxy; or

R is -(CH₂)-NR^m-(C₁₃-C₁₈ alkyl), where R^m is H, -CH₃ or

-C(O)CH₃; and

pharmaceutically acceptable salts and solvates thereof.

6. (Amended) A pharmaceutical formulation comprising said pseudomycin compound or said pharmaceutically acceptable salt or solvate thereof of Claim 2 and a pharmaceutically acceptable carrier, diluent, buffer, or excipient.

7. (Amended) A method for treating a fungal infection in an animal in need thereof, comprising the steps of administering to said animal said pseudomycin compound or said pharmaceutically acceptable salt or solvate thereof of Claim 2.

Please add the following new claims:

--16. A pharmaceutical formulation comprising said pseudomycin compound or said pharmaceutically acceptable salt or solvate thereof of Claim 1 and a pharmaceutically acceptable carrier, diluent, buffer, or excipient.--

--17. A method for treating a fungal infection in an animal in need thereof, comprising the steps of administering to said animal said pseudomycin compound or said pharmaceutically acceptable salt or solvate thereof of Claim 1...--